Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Termination of a Material Definitive AgreementItem 1.02
Five Prime Therapeutics, Inc. (“FivePrime”) and INBRX 110 LP (“Inhibrx”) entered into a Research Collaboration and License Agreement, effective July13, 2015 (the “Agreement”), to which FivePrime obtained from Inhibrx (a)an exclusive, worldwide license to antibodies to glucocorticoid-induced tumor necrosis factor receptor (“GITR”) for therapeutic and diagnostic uses, and (b)an exclusive option to obtain exclusive, worldwide licenses to multi-specific antibodies developed by Inhibrx that bind to both GITR and other targets.
On August28, 2017, FivePrime delivered to Inhibrx written notice of termination of the Agreement for convenience. to the terms of the Agreement, termination of the Agreement will become effective on December27, 2017, which is 120 days after the effective date of FivePrime’s notice of termination.
2
About Five Prime Therapeutics, Inc. (NASDAQ:FPRX)
Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).
